Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Kure

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
BMC Cancer|November 22, 2012
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabJanne B Kjersem, Tone Ikdahl, Tormod Guren, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trendsM F Ystgaard, T Å Myklebust, J Smeby, et al.
Plos One|February 6, 2014
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII StudyLine S Tarpgaard, Tormod K Guren, Bengt Glimelius, et al.
Oncotarget|October 15, 2016
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancerMaria Thomsen, Christian Kersten, Halfdan Sorbye, et al.
International Journal of Cancer|May 7, 2021
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Clinical Colorectal Cancer|January 1, 2025
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal CancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Anticancer Research|December 25, 2009
Cytogenetic effects of exposure to 2.3 GHz radiofrequency radiation on human lymphocytes in vitroInger-Lise Hansteen, Kjell O Clausen, Vera Haugan, et al.
British Journal of Cancer|June 7, 2018
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcomeMaria Thomsen, Eva Skovlund, Halfdan Sorbye, et al.
The Pharmacogenomics Journal|August 12, 2015
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatinJ B Kjersem, M Thomsen, T Guren, et al.
BMC Cancer|March 18, 2006
Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control studyCamilla Furu Skjelbred, Mona Saebø, Håkan Wallin, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
BMC Cancer|November 22, 2012
Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximabJanne B Kjersem, Tone Ikdahl, Tormod Guren, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trendsM F Ystgaard, T Å Myklebust, J Smeby, et al.
Plos One|February 6, 2014
Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII StudyLine S Tarpgaard, Tormod K Guren, Bengt Glimelius, et al.
Oncotarget|October 15, 2016
Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancerMaria Thomsen, Christian Kersten, Halfdan Sorbye, et al.
International Journal of Cancer|May 7, 2021
Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Clinical Colorectal Cancer|January 1, 2025
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal CancerJulian Hamfjord, Tormod Kyrre Guren, Bengt Glimelius, et al.
Anticancer Research|December 25, 2009
Cytogenetic effects of exposure to 2.3 GHz radiofrequency radiation on human lymphocytes in vitroInger-Lise Hansteen, Kjell O Clausen, Vera Haugan, et al.
British Journal of Cancer|June 7, 2018
Prognostic role of carcinoembryonic antigen and carbohydrate antigen 19-9 in metastatic colorectal cancer: a BRAF-mutant subset with high CA 19-9 level and poor outcomeMaria Thomsen, Eva Skovlund, Halfdan Sorbye, et al.
The Pharmacogenomics Journal|August 12, 2015
AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatinJ B Kjersem, M Thomsen, T Guren, et al.
BMC Cancer|March 18, 2006
Polymorphisms of the XRCC1, XRCC3 and XPD genes and risk of colorectal adenoma and carcinoma, in a Norwegian cohort: a case control studyCamilla Furu Skjelbred, Mona Saebø, Håkan Wallin, et al.
Pageof 9